New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - abiraterone acetate 500mg - film coated tablet - 500 mg - active: abiraterone acetate 500mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opadry purple 85f90093 sodium laurilsulfate - zytiga is indicated in combination with prednisone or prednisolone and androgen depreviation therapy (adt) for the treatment of high-risk metastatic hormone naive prostate cancer (mhnpc) or newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mhspc) zytiga is also indicated with prednisone or prednisolone for: . the treatment of patients with metastatic castration resistant prostate cancer (mcprc) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (adt) in whom chemotherapy is not yet clinically indicated . the treatment of patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mcprc) who have received prior chemotherapy containing a taxane.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - ketoconazole 200mg - tablet - 200 mg - active: ketoconazole 200mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 4mg;  ;   - film coated tablet - 4 mg - active: risperidone 4mg     excipient: colloidal silicon dioxide hypromellose   indigo carmine lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propylene glycol purified talc quinoline yellow sodium laurilsulfate titanium dioxide - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 6mg;  ;   - film coated tablet - 6 mg - active: risperidone 6mg     excipient: colloidal silicon dioxide hypromellose   lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propylene glycol purified talc quinoline yellow sodium laurilsulfate sunset yellow fcf titanium dioxide

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - haloperidol decanoate 50 mg/ml - injection (depot) - 50 mg/ml - active: haloperidol decanoate 50 mg/ml excipient: benzyl alcohol sesame oil - the maintenance therapy of psychoses, particularly for patients requiring prolonged parenteral neuroleptic therapy.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - haloperidol decanoate 100 mg/ml - injection (depot) - 100 mg/ml - active: haloperidol decanoate 100 mg/ml - the maintenance therapy of psychoses, particularly for patients requiring prolonged parenteral neuroleptic therapy.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - etravirine 100mg - tablet - 100 mg - active: etravirine 100mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose as a spray dried powder lactose magnesium stearate microcrystalline cellulose - etravirine, in combination with other antiretroviral agents is indicated for the treatment of hiv-1 infection in antiretroviral treatment-experienced adults who have evidence of viral replication and resistance to non-nucleoside transcriptase inhibitors and other antiretroviral agents.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - etravirine 200mg - tablet - 200 mg - active: etravirine 200mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose as a spray dried powder silicified microcrystalline cellulose magnesium stearate microcrystalline cellulose - etravirine, in combination with other antiretroviral agents is indicated for the treatment of hiv-1 infection in antiretroviral treatment-experienced adults who have evidence of viral replication and resistance to non-nucleoside transcriptase inhibitors and other antiretroviral agents.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base; galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base - modified release capsule - 16 mg - active: galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base excipient: diethyl phthalate ethylcellulose gelatin hypromellose iron oxide red opacode black s-1-27794 opadry clear oy-7240 sugar spheres titanium dioxide active: galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base excipient: diethyl phthalate ethylcellulose gelatin hypromellose opacode black s-1-277002 opadry clear oy-7240 sugar spheres - reminyl is indicated for the treatment of mild to moderately severe dementia of the alzheimer type.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg; galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg - modified release capsule - 24 mg - active: galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg excipient: diethyl phthalate ethylcellulose gelatin hypromellose iron oxide red iron oxide yellow opacode black s-1-277002 opadry clear oy-7240 sugar spheres titanium dioxide active: galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg excipient: diethyl phthalate ethylcellulose gelatin hypromellose opacode black s-1-277002 opadry clear oy-7240 sugar spheres - reminyl is indicated for the treatment of mild to moderately severe dementia of the alzheimer type.